Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Goldline Pharmaceutical
Price Band
₹41.0–43.0
Issue Size
₹11.61 Cr
Lot Size
3,000 shares
Min Investment
₹258,000
GMP
+₹15.0 (34.88%)
Issue Price
₹43.0
calendar_month Important Dates
bar_chart Subscription Status
Subscription data unavailable
trending_up Grey Market Premium (GMP)
GMP
+₹15.0
GMP %
+34.88%
Est. Listing
₹58.0
schedule Updated: 14 Jul 2026 15:52
Share GMP:
business About the Company
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments: Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians. Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners. Goldline InLife: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy. The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations. All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply. The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Competitive Strengths: Experienced Promoters and Management Team with Industry Knowledge and a Track Record Asset-light Business Model and Competitive Products Scalable Business Model Wide and Diverse Range of Product Offerings Strong Supplier and Vendor Relationships Established Distribution Network
payments Company Financials (₹ Cr)
As of 2025-12-31
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
| NET Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
Key Ratios
EPS
₹4.11
NAV
₹12.38
ROE
35.83%
ROCE
38.45%
RoNW
27.37%
P/B Value
3.47
P/E Ratio
10.47
Market Cap
₹41.28 Cr
PAT Margin
10.09%
Debt/Equity
1.50
Promoters
Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company 8.35 2 General Corporate Purposes 1.71 3 Issue Expense 1.55 Total 11.61
info Issue Details
pie_chart Investor Allocation
Registrar
Lead Managers / Book Running
timeline IPO Timeline
Open
12 May 2026
Close
14 May 2026
Allotment
15 May 2026
Listing
19 May 2026